Korro Bio FY2024 EPS Forecast Increased by HC Wainwright

Korro Bio, Inc. (NASDAQ:KRRO) – HC Wainwright increased their FY2024 earnings per share estimates for Korro Bio in a report released on Wednesday, November 13th. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($9.49) per share for the year, up from their prior forecast of ($9.72). HC Wainwright currently has a “Buy” rating and a $115.00 target price on the stock. The consensus estimate for Korro Bio’s current full-year earnings is ($9.63) per share. HC Wainwright also issued estimates for Korro Bio’s Q4 2024 earnings at ($2.38) EPS, Q1 2025 earnings at ($2.45) EPS, Q3 2025 earnings at ($2.58) EPS, Q4 2025 earnings at ($2.64) EPS and FY2025 earnings at ($10.19) EPS.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($2.26) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.55) by $0.29.

Several other equities analysts have also recently commented on KRRO. William Blair reaffirmed an “outperform” rating on shares of Korro Bio in a report on Wednesday, November 13th. Royal Bank of Canada boosted their price objective on Korro Bio from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Monday, October 21st. Finally, Raymond James began coverage on Korro Bio in a research report on Monday, October 21st. They issued a “strong-buy” rating and a $153.00 target price for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $142.17.

Korro Bio Trading Down 4.3 %

NASDAQ KRRO opened at $47.56 on Monday. Korro Bio has a twelve month low of $30.00 and a twelve month high of $98.00. The firm has a 50-day simple moving average of $50.05 and a 200 day simple moving average of $46.68.

Insider Transactions at Korro Bio

In related news, CFO Vineet Agarwal sold 800 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $70.00, for a total value of $56,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 5.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in KRRO. Bank of New York Mellon Corp bought a new stake in shares of Korro Bio in the 2nd quarter worth about $649,000. Rhumbline Advisers acquired a new position in Korro Bio in the second quarter valued at about $279,000. Atlas Venture Life Science Advisors LLC grew its stake in Korro Bio by 1.6% during the second quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock worth $38,515,000 after buying an additional 17,857 shares during the last quarter. Brown Brothers Harriman & Co. acquired a new stake in shares of Korro Bio during the second quarter worth approximately $28,000. Finally, Tri Locum Partners LP bought a new position in shares of Korro Bio in the second quarter valued at approximately $2,419,000. 13.18% of the stock is owned by institutional investors.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).